急性炎症性脱髓鞘性多发性神经病治疗探讨

Discussion on the Treatment of Acute Inflammatory Demyelinating Polyneuropathy

目的探析急性炎症性脱髓鞘性多发性神经病治疗体会。方法该研究选择2019年3月—2020年3月在该院接受治疗的急性炎症性脱髓鞘性多发性神经病患者共计52例作为主要分析对象,收集所有患者治疗时的相关治疗进行回顾性分析。根据1∶1的比例将所有患者分为对照组和观察组两组,每组26例,所有患者均接受临床治疗,但治疗方法不同,分别是对照组采用激素治疗,观察组采用免疫球蛋白治疗。两组使用不同方法治疗后,观察和分析患者的临床状况,并记录相关数据,尤其是治疗后两组患者不良反应发生率、治疗总有效率等数据要详细记录。同时将两组记录后的数据进行比较。结果采用免疫球蛋白治疗的观察组和激素治疗的对照组比较不良反应发生率,分别是3.85%(1/26)、23.07%(6/26),对照组相对较高,差异有统计学意义(χ^(2)=4.127,P<0.05);此外两组治疗效果比较,观察组为(96.15%)相对于对照组(76.92%)较高,差异有统计学意义(χ^(2)=4.372,P<0.05)。结论在急性炎症性脱髓鞘性多发性神经病治疗中使用激素治疗虽然具有一定的治疗效果,但是治疗期间水钠潴留、继发感染、上消化道出血、骨质疏松等不良反应的发生率较高。而使用免疫球蛋白治疗不仅能够提高治疗效果,还能够减少不良反应的发生,对患者治疗安全性的提高有着重要意义。综合考虑,免疫球蛋白治疗效果要优于激素治疗,建议将其作为临床中首选治疗方案。

Objective To explore the treatment experience of acute inflammatory demyelinating polyneuropathy.Methods The study selected 52 patients with acute inflammatory demyelinating polyneuropathy who were treated in the hospital from March 2019 to March 2020 as the main analysis objects,and collected the relevant treatments of all patients during treatment for retrospective analysis.According to a ratio of 1:1,all patients were divided into two groups:control group and observation group,each with 26 cases.All patients received clinical treatment,but the treatment methods were different.The control group was treated with hormones and the observation group was treated with immunoglobulin.treatment.After the two groups are treated with different methods,observe and analyze the clinical conditions of the patients,and record relevant data,especially the incidence of adverse reactions,the total effective rate of treatment and other data of the two groups of patients after treatment should be recorded in detail.Simultaneously compare the recorded data of the two groups.Results Compared with the observation group treated with immunoglobulin and the control group treated with hormones,the incidence of adverse reactions was 3.85%(1/26)and 23.07%(6/26),the control group was relatively high.The difference was statistically significant(χ^(2)=4.127,P<0.05);In addition,the treatment effect of the two groups was compared,the observation group(96.15%)was higher than the control group(76.92%),and the difference was statistically significant(χ^(2)=4.372,P<0.05).Conclusion Although the use of hormone therapy in the treatment of acute inflammatory demyelinating polyneuropathy has a certain therapeutic effect,the incidence of adverse reactions such as higher water and sodium retention,secondary infection,upper gastrointestinal bleeding,and osteoporosis during the treatment period.The use of immunoglobulin therapy can not only improve the therapeutic effect,but also reduce the occurrence of adverse reactions,which is of great significance for improving the safety of patients'treatment.After comprehensive consideration,immunoglobulin therapy is better than hormone therapy,and it is recommended to be the first choice in clinical treatment.